Actelion nominates Mr. John J. Greisch for election to the Board of Directors
* Reuters is not responsible for the content in this press release.
For best results when printing this announcement, please click on the link below: http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130314:nHUGcZ9J Actelion Pharmaceuticals Ltd / Actelion nominates Mr. John J. Greisch for election to the Board of Directors . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. ALLSCHWIL/BASEL, SWITZERLAND - 14 March 2013- Actelion Ltd (SIX: ATLN) today issued the formal invitation to the upcoming Annual General Meeting (AGM) of shareholders on behalf of the Board of Directors. At the AGM the Board is nominating Mr. John J. Greisch to the Board of Directors. Mr. Greisch is currently serving as the President and Chief Executive Officer of Hill-Rom Holdings, Inc. Jean-Pierre Garnier, Chairman of the Board of Directors, commented: "As a current CEO, John understands the challenges that face companies operating in the current economic and business climate. I believe John's strong track record of success in the healthcare industry will add significant practical business acumen to Actelion's Board." In addition, delivering on Actelion's commitment to value creation for all stakeholders, the Board is proposing a 25% increase in the dividend payment, increasing the payment to CHF 1.00 per share AGENDA FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS 2013 1Approval of the Business Report consisting of the Annual Report, the Annual Statutory Accounts and the Consolidated Accounts as of 31 December 2012 2Appropriation of Available Earnings and Distribution Against Reserve from Capital Contribution 3Consultative Vote on Compensation Report 4Discharge of the Board of Directors and of the Senior Management 5Reduction of Share Capital by Cancellation of Repurchased Shares 6Board Elections6.1 Re-Election of Mr. Werner Henrich6.2 Re-Election of Mr. Armin Kessler6.3 Re-Election of Mr. Jean Malo6.4 Election of Mr. John J. Greisch as New Board Member 7Election of the Statutory Auditors NOTES TO SHAREHOLDERS The Annual General Meeting of Shareholders to approve the Business Report of the year ending 31 December 2012 will be held on 18 April 2013 at 14.00 CEST at the Congress Center, Messe Basel, Switzerland. The invitation has been published in the Swiss Official Gazette of Commerce (Schweizerisches Handelsamtsblatt) and is available, together with the company's Annual Report, on www.actelion.com. In order to attend and vote at the Annual General Meeting of Shareholders, shareholders must have been registered in the Company's shareholder register by 9 April 2013 at the latest. ### NOTES TO EDITORS ABOUT MR JOHN J. GREISCH Mr. John J. Greisch is currently President (as Executive Director) and Chief Executive Officer of Hill-Rom Holdings, Inc., a leading medical supplier of patient support systems such as hospital beds, therapeutic surfaces and stretchers. Under Mr. Greisch's leadership, Hill-Rom increased its investments in research and development, introducing new smart bed technology and new surfaces to the market as well as expanding its Singapore-based Asia-Pacific Innovation Center. Before joining Hill-Rom, Mr. Greisch spent seven years at Baxter International, Inc. in various executive positions in corporate finance, operations and general management. From 2004-2006, he served as Chief Financial Officer and from 2006-2009 as President International Operations. Mr Greisch earned a Bachelor's degree in Business Administration from the Miami University, US and a Master's Degree in Management (MBA equivalent) from the Northwestern University in Illinois, US Mr. Greisch also serves on the Board of Lurie Children's Hospital in Chicago and is a past member of the Business School Advisory Board for Miami University's Farmer School of Business. ABOUT ACTELION LTD. Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer(R), an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer(R) through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Founded in late 1997 Actelion is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 2,400 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI(R)). For further information please contact: Roland Haefeli Senior Vice President, Head of Investor Relations & Public Affairs Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil +41 61 565 62 62 +1 650 624 69 36 www.actelion.com http://www.actelion.com/ Media Release PDF http://hugin.info/131801/R/1685097/551972.pdf ---------------------------------------------------------------------------------------------------- This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE HUG#1685097 --- End of Message --- Actelion Pharmaceuticals Ltd Gewerbestrasse 16 Allschwil Switzerland ISIN: CH0010532478;